During the 64th annual meeting of ASH, again hundreds of interesting oral abstracts and poster presentations in the field of acute myeloid leukaemia were discussed. In this article, we will highlight some of the most promising data in the field of novel therapeutic agents, with interesting studies on gilteritinib and quizartinib. Furthermore, several trials assessed new induction strategies and reported on biomarker and/or minimal residual disease investigations. Finally, we discuss some practice-changing data from the ASAP and VIALE-A trials.
(BELG J HEMATOL 2023;14(1):30–5)